The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: A phase II study

International Journal of Cancer

Volumn 126, Issue 8, 2010, Pages 1806-1816

  Gutteridge, Eleanor ^b   Agrawal, Amit ^b   Nicholson, Robert ^a   Cheung, Kwok Leung ^b   Robertson, John ^b   Gee, Julia ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; EGFR TKI; Gefitinib; Iressa; Ramoxifenresistant

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GEFITINIB; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ACNE; ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; BRONCHOPNEUMONIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FEMALE; HEART ARREST; HORMONE RESISTANCE; HUMAN; LETHARGY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RASH; STAINING; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING; BIOSYNTHESIS; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MORTALITY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 77949882440     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24884     Document Type: Article

References (59)

1. NicholsonRI,McClellandRA,FinlayP,EatonCL,GullickWJ,DixonAR,RobertsonJF, EllisIO,BlarneyRW.RelationshipbetweenEGF-R,c-erbB- 2proteinexpressionandKi67immunostaininginbreastcancerandhormonesensitivity. EurJCancer1993;29A:1018-1023(Pubitemid23126705)
2. NicholsonRI,McClellandRA,GeeJM,ManningDL,CannonP,RobertsonJF,EllisIO, BlarneyRW.Epidermalgrowthfactorreceptorexpressioninbreastcancer: associationwithresponse-endocrinetherapy.BreastCancerResTreat1994;29: 117-125(Pubitemid24104843)
3. SainsburyJR,MalcolmAJ,AppletonDR,FarndonJR,HarrisAL. Presenceofepidermalgrowthfactorreceptorasanindicatorofpoorprognosisinpatients withbreastcancer.JClinPathol1985;38:1225-1228(Pubitemid16215034)
4. Lewis S, Locker A, Todd JH, Bell JA, Nicholson R, Elst.on CW, Blarney RW, Ellis IO. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 1990; 43: 385-389
5. Coombes RC, Barrett-Lee P, Luqmani Y. Growth factor expression in breast tissue. J Steroid Biochem Mol Biol 1990; 37: 833-836
6. Bundred NJ, Chan K, Anderson NG. Studies of epidermal growth factor receptor inhibition in breast cancer. Endocr Relat Cancer 2001; 8: 183-189 (Pubitemid 32947640)
7. ChanKC,KnoxWF,GeeJM,MorrisJ,NicholsonRI,PottenCS,BundredNJ. Effectofepidermalgrowthfactorreceptortyrosinekinaseinhibitiononepithelialprolif erationinnormalandpremalignantbreast.CancerRes2002;62:122-128(Pubitemid34073995)
8. LuC,SpeersC,ZhangY,XuX,HillJ,SteinbisE,CelestinoJ,ShenQ,KimH,HilsenbeckS, MohsinSK,WakelingA,etal. Effectofepidermalgrowthfactorreceptorinhibitorondevelopmentofestrogenreceptor- negativemammarytumors.JNatlCancerInst2003;95:1825-1833(Pubitemid38054683)
9. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogenactivated protein kinase. J Clin Oncol 2005; 23: 2469-2476 (Pubitemid 47050837)
10. Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA, Ciardiello F, Miller WR, Dowsett M, Barrett-Lee P, Robertson JF, et al. Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer 2005;12 Suppl l:S1-7.
11. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/ c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifenresistant MCF-7 cells. Endocrinology 2003; 144:1032-1044 (Pubitemid 36262870)
12. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI. The antiepidermal growth factor receptor agent gefitinib (ZD 1839/ Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003; 144: 5105-5117 (Pubitemid 37378426)
13. Meric JB, Faivre S, Monnerat C, Adi Vago N, Le Chevalier T, Armand JP, Raymond E. [Zd 1839 "Iressa"]. Bull Cancer 2000;87: 873-876 (in French).
14. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. Z.D1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001;94:774-782 (Pubitemid 33032823)
15. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6: 4885-4892
16. ShouJ,MassarwehS,OsborneCK,WakelingAE,AliS,WeissH,SchiffR. Mechanismsoftamoxifenresistance:increasedestrogenreceptor-HER2/ neucross-talkinER/HER2-positivebreastcancer.JNatlCancerInst2004;96: 926-935(Pubitemid38868139)
17. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-4302 (Pubitemid 35266289)
18. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin. D, Eek R, Horai T, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237-2246 (Pubitemid 46621858)
19. Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated nonsmall cell lung cancer patients. Semin Oncol 2003:30(1 Suppl l):30-38 (Pubitemid 36307615)
20. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Celia D, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158 (Pubitemid 37432975)
21. Albain K, Elledge R, Gradishar WJ, Hayes DF, Rowinsky E, Hudis C, Pusztai L, Tripathy D, Modi S, Rubi S. Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 2002; 76(Suppl):S33.
22. von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Luck HJ, Kettner E, Hilfrich J, Eiermann W, Torode J, Schneeweiss A. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005;89: 165-172
23. Jones HE, Goddard L, Gee JM, Hiscox. S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11: 793-814. (Pubitemid 40065552)
24. Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat 2004; 87: 167-180 (Pubitemid 39237793)
25. Deb TB, Su L, Wong L, Bonvini E, Wells A, David M, Johnson GR. Epidermal growth factor (EGF) receptor kinaseindependent signaling by EGF. J Biol Chem 2001; 276: 15554-15560 (Pubitemid 37373452)
26. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Loss of PTEN/ MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22: 2812-2822 (Pubitemid 36609595)
27. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253 (Pubitemid 23008970)
28. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally welltolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20: 3815-3825
29. Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305-5313 (Pubitemid 46206984)
30. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxei with placebo plus paclitaxei as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26: 5544-5552
31. Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJ. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumabcontaining regimens. Ann Oncol 2009;20: 1026-1031
32. Francis P, GM, Gebski V, Harvey V, Karapetis C, Chan A, Snyder R, Forbes J;for Australian New Zealand Breast Cancer Trials Group (ANZ BCTG), Newcastle, NSW, Australia.Gentinib has a low clinical benefit rate in advanced breast cancer patients. Presented at the 28th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, December 10, 2005.
33. Winer E, Cobleigh M, Dickler M, Miller K, Fehrenbacher L, Jones C, Justice R. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002; 76(Suppl 1): S115.
34. Cheung KL. Endocrine therapy for breast cancer: an overview. Breast 2007; 16: 327-343 (Pubitemid 47109203)
35. Cheung KL, Nicholson RI, Blarney RW, Robertson JF. Selection of primary breast cancer patients for adjuvant endocrine therapy-is oestrogen receptor alone adequate? Breast Cancer Res Treat 2001;65: 155-162
36. Robertson JF, Cannon PM, Nicholson RI, Blarney RW. Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer. Int J Biol Markers 1996; 11: 29-35.
37. Maynard PV, Davies CJ, Blarney RW, Elston CW, Johnson J, Griffiths K. Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer 1978; 38: 745-748
38. Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, Gridelli C, Catalano G, et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006; 94: 1604-1609 (Pubitemid 43924921)
39. Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triplenegative breast cancer. Ann Oncol 2009; 20: 862-867
40. Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Nicholson RI. New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145. Int J Cancer 1997;71:1010-1018 (Pubitemid 27252884)
41. Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson. JF, Ellis IO, Nicholson RI. Heregulin betal drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res 2007:9:R50. (Pubitemid 350187472)
42. Brltton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI, Bidirectional cross talkbetween ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2006;96: 131-146
43. Bailey LR, Kris M, Wolf M, Kay A, Averbuch S, Askaa J, Janas M, Schmidt K, Fukuoka M. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving Gefitinib (Iressa, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 2003; 44: 1362.
44. Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 1998; 48: 11-20. (Pubitemid 28073529)
45. ChangJ,PowlesTJ,AllredDC,AshleySE,MakrisA,GregoryRK,OsborneCK,DowsettM. Predictionofclinicaloutcomefromprimarytamoxifenbyexpressionofbiologicmarker sinbreastcancerpatients.ClinCancerRes2000;6:616-621(Pubitemid30111487)
46. Kenny FS, Willsher PC, Gee JM, Nicholson R, Pinder SE, Ellis IO, Robertson JF. Change in expression of ER, bcl-2 and MIBl on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Res Treat 2001; 65: 135-144 (Pubitemid 32193617)
47. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167-170 (Pubitemid 47232611)
48. Polychrome A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor- positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005; 6: 383-391 (Pubitemid 40753744)
49. Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 2008; 26: 897-906. (Pubitemid 351398082)
50. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Insulin-like growth factor-I receptor signaling in tamoxifenresistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005; 146: 4609-4618 (Pubitemid 41446598)
51. Willsher PC, Beaver J, Pinder S, Bell JA, Ellis IO, Blarney RW, Robertson JF. Prognostic significance of serum c-erbB-2 proteinin breast cancer patients. Breast Cancer Res Treat 1996; 40: 251-255 (Pubitemid 26336120)
52. WillsherPC,PinderSE,GeeJM,EllisIO,ChanSY,NicholsonRI,BlarneyRW, RobertsonJF.C-erbB2expressionpredictsresponse- preoperativechemotherapyforlocallyadvancedbreastcancer.AnticancerRes1998;18(5B): 3695-3698(Pubitemid28564249)
53. Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 2008;14: 6277-6283
54. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon. P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, Koehler MT, Rojo F. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005; 23: 5323-5333 (Pubitemid 46206986)
55. LeeAV,JacksonJG,GoochJL,HilsenbeckSG,Coronado-HeinsohnE,OsborneCK,YeeD. Enhancementofinsulin-likegrowthfactorsignalinginhumanbreastcancer: estrogenregulationofinsulinreceptorsubstrate-1expressioninvitroandinvivo. MolEndocrinol1999;13:787-796(Pubitemid30645331)
56. Stein W, Hortobagyi GN, Blumenschein GR. Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. J Surg Oncol 1983; 22: 45-46 (Pubitemid 13179723)
57. Osborne K, Neven P, Dirix L, Mackey J, Robert J, Underbill C, Gutierrez C, Magill P, Hargreaves L. Randomized Phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 2007;106(Suppl 1): S107.
58. Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007; 25: 3816-3822 (Pubitemid 47477255)
59. Cristofanilli M, Valero V, Mangalik A, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Magill P. A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefitinib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol 2008; 26(Suppl):abstr 1012.